World-Class Drug

Development Capabilities

Our
Pipeline

Program

Indication

Discovery

In Vitro

In Vivo

Preclinical

Lead Op

IND Enabling

Clinical

Stage 1

Stage 2

Stage 3

Global Rights

PLN-74809

Dual selective inhibitor of
αvβ6vβ1

WHOLLY OWNED

Idiopathic Pulmonary Fibrosis (IPF)

Primary Sclerosing Cholangitis (PSC)

PLN-74809 is an oral small-molecule dual-selective inhibitor of αvβ6 and αvβ1 integrins for the treatment of IPF and PSC.

While present at very low levels in healthy tissues, these integrins are upregulated in the lungs of IPF patients and the bile ducts of PSC patients where they activate TGF-β, a key driver of the fibrotic process. Blocking these integrins is designed to stop TGF-β activation, potentially halting the growth of scar tissue.

Read More

PLN-74809 is an oral small-molecule dual-selective inhibitor of αvβ6 and αvβ1 integrins for the treatment of IPF and PSC.

While present at very low levels in healthy tissues, these integrins are upregulated in the lungs of IPF patients and the bile ducts of PSC patients where they activate TGF-β, a key driver of the fibrotic process. Blocking these integrins is designed to stop TGF-β activation, potentially halting the growth of scar tissue.

Read More

Oncology

Inhibitor of αvβ8

Solid Tumors

Our oncology program focuses on selective inhibition of αvβ8, an integrin that can activate TGF-β in the tumor microenvironment, causing an anti-inflammatory effect and potential resistance to immuno-oncology therapeutics such as checkpoint inhibitors.

Read More

Muscular Dystrophy

Anti-integrin mAb

Other Muscular Dystrophies

Muscular dystrophy comprises a group of inherited diseases, all characterized by inborn errors in dystrophin, a protein that anchors muscle cells to the extracellular matrix and facilitates contraction.  The lack of dystrophin results in muscle cell damage upon contraction, causing a progressive loss of muscle function over time.

Read More

PLN-1474

Selective inhibitor of αvβ1

PARTNERED

NASH-Associated Liver Fibrosis

Our second product candidate, PLN-1474, is a small-molecule selective inhibitor of αvβ1 for the treatment of late stage liver fibrosis associated with nonalcoholic steatohepatitis (NASH). The integrin αvβ1 activates TGF-β in the liver, leading to fibrosis and, potentially, liver failure.

Read More

Expanding Possibilities

We are evaluating the potential benefits of our product candidates outside of their lead indications. Our product candidates have shown anti-fibrotic activity in multiple animal models as well as live human tissues in indications outside of IPF, PSC, and NASH. We will continue to evaluate additional indications to maximize the potential of our pipeline.